Product
Hiltonol
Aliases
poly-ICLC
3 clinical trials
4 indications
Indication
Breast CancerIndication
Smoldering Plasma Cell MyelomaIndication
GliomaIndication
malignantClinical trial
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)Status: Recruiting, Estimated PCD: 2025-04-01